Taysha Gene Therapies, Inc. Common Stock
Here’s whether Taysha Gene Therapies, Inc. Common Stock (TSHA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 37 — healthy momentum range; strong 1-year return of +113.1%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-3.00% over 10 days); 3-month momentum negative (-13.8%). Currently 24.4% off its 52-week high. Score: +1/7.
TSHA is holding above its long-term 200-day MA ($5.23) but has slipped below the 50-day MA ($5.98), pointing to short-term weakness in an otherwise intact trend. An RSI of 37.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +113.1% compares to +16.5% for SPY (beat the market by 96.7%). The current 24.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.